Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + atezolizumab + durvalumab + benmelstobart + toripalimab + serplulimab-Tianjin Medical University Cancer Institute and Hospital-small cell lung cancer
- Development stage
- Unknown
- Lead developer
- Tianjin Medical University Cancer Institute and Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This refers to the immune checkpoint inhibitor (ICI) component of the shared control arm in the BUTTONS-001 umbrella trial (NCT07172412), conducted by Tianjin Medical University Cancer Institute and Hospital. The protocol evaluates the efficacy and safety of various PD-1 and PD-L1 inhibitors—specifically tislelizumab, atezolizumab, durvalumab, benmelstobart, toripalimab, and serplulimab—in combination with standard-of-care chemotherapy (etoposide plus cisplatin or carboplatin) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Patients are assigned to one of these ICIs as part of a biomarker-integrated study design that also explores experimental combinations with DLL3-targeted CAR-NK cells, selinexor, or anlotinib. These monoclonal antibodies target the PD-1/PD-L1 pathway to prevent tumor-mediated immune evasion and enhance anti-tumor T-cell activity.
- Other names
- ICI + chemotherapy control arm
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on tislelizumab + atezolizumab + durvalumab + benmelstobart + toripalimab + serplulimab-Tianjin Medical University Cancer Institute and Hospital-small cell lung cancer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + atezolizumab + durvalumab + benmelstobart + toripalimab + serplulimab-Tianjin Medical University Cancer Institute and Hospital-small cell lung cancer.